News Release

Messenger RNA therapy in mice

Peer-Reviewed Publication

Proceedings of the National Academy of Sciences

Arginase mRNA

image: This is a microscopic image of the liver showing arginase mRNA delivered by lipid nanoparticle as small brown areas within hepatocytes. view more 

Credit: Image courtesy of Kristine E. Burke

Genetic deficiency of the liver enzyme arginase interrupts the urea cycle and causes a range of symptoms in humans, and a study finds that in mice with a genetic arginase deficiency, administration of liver-targeted nanoparticles that carried a messenger RNA for the arginase gene resulted in restored urea cycle function, ammonium metabolism, and prolonged lifespan.

Article #19-06182: "Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency," by Brian Truong et al.

MEDIA CONTACT: Gerald S. Lipshutz, University of California, Los Angeles, CA; e-mail: glipshutz@mednet.ucla.edu

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.